Figure 3. Cost-effectiveness Acceptability Curves.
The curves show the probabilities of being cost-effective at different willingness-to-pay thresholds for atezolizumab plus bevacizumab and sorafenib. QALY, quality-adjusted life-year.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.